Associated Papers
Baseline mutational profiles of patients with carcinoma of unknown primary origin enrolled in the CUPISCO study.
Westphalen CB et al.
Esmo Open, 2023
37922692 (PubMed )
Supplement: mmc1.docx
Dual blockade of BRD4 and ATR/WEE1 pathways exploits ARID1A loss in clear cell ovarian cancer.
Kinose Y et al.
Research Square, 2023
Loss of HES1 Expression is Associated with Extracellular Matrix Remodeling and Tumor Immune Suppression in KRAS Mutant Colon Adenocarcinomas.
Wang L et al.
Research Square, 2023
Effects of TP53 Mutations and miRs on Immune Responses in the Tumor Microenvironment Important in Pancreatic Cancer Progression.
McCubrey JA et al.
Cells, 2022
Genomic Features of Organ-Specific Metastases in Lung Adenocarcinoma.
Feng A et al.
Frontiers in Oncology, 2022
In vitro behavior and UV response of melanocytes derived from carriers of CDKN2A mutations and MC1R variants.
Hernando B et al.
Pigment Cell & Melanoma Research, 2019
The distinct metabolic phenotype of lung squamous cell carcinoma defines selective vulnerability to glycolytic inhibition.
Goodwin J et al.
Nature Communications, 2017
28548087 (PubMed )
Supplement: ncomms15503-s1.pdf
Comprehensive genomic profiling of 295 cases of clinically advanced urothelial carcinoma of the urinary bladder reveals a high frequency of clinically relevant genomic alterations.
Ross JS et al.
Cancer, 2016
Germline hemizygous deletion of CDKN2A-CDKN2B locus in a patient presenting with Li-Fraumeni syndrome.
Chan SH et al.
Npj Genomic Medicine, 2016
29263814 (PubMed )
Supplement: npjgenmed201615-s1.doc
Population-based prevalence of CDKN2A mutations in Utah melanoma families.
Eliason MJ et al.
The Journal of Investigative Dermatology, 2006
Germline splicing mutations of CDKN2A predispose to melanoma.
Loo JC et al.
Oncogene, 2003
Select a paper to view details